QHG of Enterprise INC
QHG of Enterprise INC was paid $3.94M by Medicaid between Jan 2018 and Dec 2024, across 72 billing codes. Its largest line is 99283, emergency room visit (moderate) — 31% of everything it billed.
ENTERPRISE, AL 36330
Next to other General Acute Care Hospital providers in Alabama
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 31,179 | $559K | |
| 2019 | 36,434 | $583K | |
| 2020 | 19,652 | $321K | |
| 2021 | 24,098 | $453K | |
| 2022 | 33,375 | $673K | |
| 2023 | 31,595 | $814K | |
| 2024incomplete | 17,700 | $536K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 31% | 32,730 | 29,137 | $1.23M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 14,709 | 12,835 | $869K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 5.6% | 14,985 | 13,584 | $220K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.6% | 945 | 840 | $182K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 4.0% | 13,529 | 12,250 | $157K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 3.2% | 4,982 | 4,577 | $128K |
| 80053 | Comprehensive metabolic panel | 3.1% | 13,031 | 11,271 | $122K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.0% | 15,718 | 13,601 | $119K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 3.0% | 3,124 | 2,742 | $119K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.0% | 3,089 | 2,796 | $118K |
| 87081 | 2.7% | 11,351 | 10,327 | $105K | |
| 81001 | 1.7% | 19,415 | 16,743 | $69K |
60 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.4% | 1,369 | $57K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 709 | $51K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 1.2% | 243 | $48K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 313 | $44K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.0% | 2,489 | $41K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,709 | $31K |
| 59025 | Fetal non-stress test | <1% | 4,971 | $24K |
| 87420 | <1% | 1,259 | $20K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,006 | $20K |
| 81025 | <1% | 6,019 | $19K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,766 | $17K |
| 83735 | <1% | 2,601 | $15K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,954 | $15K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 234 | $14K |
| 84484 | <1% | 1,945 | $12K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 26 | $11K |
| 82553 | <1% | 844 | $8K | |
| 83690 | <1% | 1,173 | $7K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,049 | $6K |
| 82550 | <1% | 888 | $5K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 226 | $5K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 169 | $4K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 78 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,147 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 307 | $3K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 167 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,517 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 296 | $2K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 24 | $2K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 73 | $1K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 50 | $1K |
| 81003 | <1% | 311 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 39 | $706.42 |
| 87340 | <1% | 60 | $684.90 | |
| 80061 | Lipid panel | <1% | 44 | $680.55 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,309 | $602.43 |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 18 | $569.66 |
| 86592 | <1% | 78 | $387.84 | |
| 76801 | <1% | 14 | $377.44 | |
| 86762 | <1% | 18 | $306.74 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 32 | $278.38 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 349 | $248.08 |
| 84702 | <1% | 14 | $206.28 | |
| 86850 | <1% | 38 | $183.30 | |
| 84550 | <1% | 43 | $174.72 | |
| 87186 | <1% | 36 | $171.87 | |
| 83615 | <1% | 42 | $168.00 | |
| 87077 | <1% | 37 | $152.66 | |
| 84439 | <1% | 12 | $121.08 | |
| 84156 | <1% | 40 | $107.76 | |
| 81002 | <1% | 28 | $86.71 | |
| 86900 | <1% | 38 | $85.54 | |
| 86901 | <1% | 34 | $81.50 | |
| 82570 | <1% | 23 | $80.64 | |
| 87210 | <1% | 14 | $72.60 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 19 | $51.25 |
| 85027 | <1% | 12 | $16.11 | |
| 99214 | Doctor's office visit, returning patient (more involved) | 0% | 60 | $0.00 |
| 82962 | 0% | 29 | $0.00 | |
| 99213 | Doctor's office visit, returning patient (routine) | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Northwest Hospital LLC | Tucson, AZ | $47.81M |
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.